Full video transcriptClick to expand
Auto-generated transcript of @x1op03's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00It's typically the result of very aggressive weight loss methods.
- 0:03It was the worst decision I ever made.
- 0:05So if this is a warning to anyone, please, if you're thinking.
- 0:08Taking the number one spot is Lottie Moss.
- 0:10And her story is honestly the most disturbing example of how dangerous the
- 0:14Ozempic trend has become.
- 0:16Lottie, Kate Moss's 26-year-old half-sister and a model herself didn't just experience
- 0:21Ozempic face.
- 0:22She ended up in the hospital with seizures after what she now calls the worst decision I ever made.
- 0:27Here's what happened.
- 0:28Lottie obtained Ozempic through unofficial channels and was taking a dosage meant for
- 0:32people weighing over 220 pounds while she only weighed around 110 pounds.
- 0:37That's like taking medication designed for someone twice your size.
- 0:40In just two weeks, she dropped from 132 pounds to 116 pounds, which is an incredibly
- 0:47dangerous rate of weight loss.
- 0:48The physical changes during this period were shocking.
- 0:51Her face became severely hollowed with her cheekbones jutting out dramatically and her
- 0:55eyes appearing sunken into her skull.
- 0:58She looked skeletal and aged far beyond her 26 years.
- 1:02Photos from this period show someone who appeared genuinely ill, not someone who had
- 1:06achieved healthy weight loss.
- 1:08Lottie has been brutally honest about her experience, documenting it on her dream on podcast.
- 1:13She described the whole ordeal as terrifying and warned other people not to make the same mistake.
- 1:18The seizures were caused by severe dehydration, a known side effect that becomes dangerous when
- 1:23combined with rapid weight loss.
- 1:24What makes Lottie's case even more disturbing is that she's young and was already thin before
- 1:29starting the medication.
Ozempic 'gone wrong': separating celebrity fear from clinical fact
Quick answer
Semaglutide and other GLP-1 receptor agonists are FDA-approved for type 2 diabetes management and chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Using these medications in individuals who are already at a healthy or low body weight has no established clinical evidence base and carries real risks including excessive caloric restriction, electrolyte disturbance from GI side effects, and disordered eating reinforcement. Seizures are not a listed or expected adverse effect of semaglutide, though severe electrolyte imbalance from prolonged vomiting or dehydration could in theory contribute to neurological events as a downstream complication.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic 'gone wrong': separating celebrity fear from clinical fact, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic 'gone wrong': separating celebrity fear from clinical fact" from X03. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide and other GLP-1 receptor agonists are FDA-approved for type 2 diabetes management and chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic gone wrong shocking celebrity transformation that ba." In this clip, the useful excerpt is: "It's typically the result of very aggressive weight loss methods." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide and other GLP-1 receptor agonists are FDA-approved for type 2 diabetes management and chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide and other GLP-1 receptor agonists are FDA-approved for type 2 diabetes management and chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Using these medications in individuals who are already at a healthy or low body weight has no established clinical evidence base and carries real risks including excessive caloric restriction, electrolyte disturbance from GI side effects, and disordered eating reinforcement. Seizures are not a listed or expected adverse effect of semaglutide, though severe electrolyte imbalance from prolonged vomiting or dehydration could in theory contribute to neurological events as a downstream complication.
- Semaglutide is FDA-approved for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. It has no approved indication for individuals who are already underweight or at a healthy weight.
- Seizures are not a listed adverse effect of semaglutide in FDA prescribing information or in major clinical trials including STEP 1 (Wilding et al., 2021, NEJM), which enrolled over 1,900 participants.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide is FDA-approved for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. It has no approved indication for individuals who are already underweight or at a healthy weight.
- Seizures are not a listed adverse effect of semaglutide in FDA prescribing information or in major clinical trials including STEP 1 (Wilding et al., 2021, NEJM), which enrolled over 1,900 participants.
- Semaglutide dosing is titrated by tolerability, not by patient body weight. The claim that specific doses are 'meant for people over 220 pounds' misrepresents how this drug is actually prescribed.
- GI side effects including nausea, vomiting, and diarrhea occur in a significant portion of semaglutide users. Severe, prolonged vomiting can cause electrolyte imbalances, which carry their own serious risks.
- Obtaining semaglutide or any prescription GLP-1 medication through unofficial or unregulated channels means no verification of drug purity, concentration, or dose, and no clinical monitoring if adverse effects occur.
- Rapid weight loss at a rate exceeding 1 to 2 pounds per week is associated with muscle mass loss, reduced bone density, and cardiovascular strain, particularly in individuals already at low body weight.
- The specific medical narrative in this video, including the weight figures, dosing details, and seizure causation, goes beyond what Lottie Moss has publicly confirmed and should not be treated as a factual clinical account.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @x1op03 actually say?
The creator claims model Lottie Moss, Kate Moss's half-sister, ended up hospitalized with seizures after obtaining semaglutide through unofficial channels and taking a dose "meant for people weighing over 220 pounds" while she weighed around 110 pounds. They say she dropped from 132 to 116 pounds in two weeks, that her face became "severely hollowed," and that the seizures were caused by "severe dehydration, a known side effect" of the drug. They frame this as a cautionary tale about the dangers of unsupervised GLP-1 use.
The video blends some real publicly documented details with significant clinical embellishments. Lottie Moss has discussed difficult experiences with her weight and health on her podcast. But the specific clinical chain of events presented here, particularly the seizure-dehydration causation, is not well-sourced and includes details that appear either fabricated or distorted beyond what she actually reported.
Does the science back this up?
Semaglutide does carry real risks when misused, especially at high doses in low-weight individuals, but the specific mechanism described here is oversimplified to the point of being misleading. Seizures are not a documented or expected side effect of semaglutide in the clinical literature.
The most common adverse effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, and reduced appetite. Severe and prolonged vomiting can lead to dehydration and electrolyte imbalances, and severe electrolyte disturbances, particularly hyponatremia or hypokalemia, can in theory precipitate seizures. But that is a multi-step physiological chain, not a direct drug effect. The creator presents it as if dehydration is a simple, expected side effect that straightforwardly causes seizures, which compresses a complicated potential cascade into something that sounds almost inevitable.
Wilding et al. (2021, NEJM) in the STEP 1 trial documented nausea in roughly 44% of participants and serious adverse events in a small minority, but seizures were not among them. Rapid weight loss in already-thin individuals does carry cardiovascular and metabolic risks, but the framing here outpaces the evidence.
What did they get wrong (or right)?
Credit where it is due: the core warning, that taking high-dose semaglutide without medical supervision, especially when already underweight, is genuinely dangerous, is correct. That is real harm-reduction messaging.
But several specific claims are either unverifiable or inaccurate. The assertion that she was taking a dose "meant for people weighing over 220 pounds" is not documented anywhere in Lottie Moss's public statements. Semaglutide dosing is not weight-tiered in that way clinically; it is titrated by tolerability and indication, not by a weight threshold. The FDA-approved maintenance dose for weight management is 2.4mg weekly regardless of starting weight, per the Wegovy prescribing information.
The "she looked skeletal and aged far beyond her 26 years" language is editorializing over photos, not clinical observation. And the detail that "seizures were caused by severe dehydration, a known side effect" presents speculation as established fact. The creator has taken a real person's real public struggle and constructed a specific, dramatic medical narrative around it that goes well beyond what has actually been documented or confirmed.
What should you actually know?
Unsupervised use of GLP-1 receptor agonists is a legitimate public health concern, and that part of this video's message is worth taking seriously. Semaglutide obtained through unofficial or unregulated channels carries real risks: unknown purity, incorrect concentration, and zero medical oversight if something goes wrong.
Using GLP-1 medications when you are already at a low body weight or underweight is clinically inappropriate. These drugs were studied in populations with obesity or overweight plus a metabolic comorbidity. The STEP 1 trial excluded participants with a BMI under 30. Someone at 110 pounds has no clinical basis for this medication and faces meaningful risks from further caloric suppression and rapid weight loss, including muscle loss, bone density reduction, and cardiovascular strain.
If you are considering any GLP-1 therapy, the starting point is a licensed clinician who can review your full health picture, not a TikTok comment section or an unofficial online source. Regulated telehealth platforms exist specifically to provide that oversight.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
X03 · TikTok creator
4.2K views on this video
OZEMPIC GONE WRONG — Shocking Celebrity Transformation That Backfired #celb #viral_video
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide?
Semaglutide is FDA-approved for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. It has no approved indication for individuals who are already underweight or at a healthy weight.
What does the video say about seizures?
Seizures are not a listed adverse effect of semaglutide in FDA prescribing information or in major clinical trials including STEP 1 (Wilding et al., 2021, NEJM), which enrolled over 1,900 participants.
What does the video say about semaglutide dosing?
Semaglutide dosing is titrated by tolerability, not by patient body weight. The claim that specific doses are 'meant for people over 220 pounds' misrepresents how this drug is actually prescribed.
What does the video say about gi side effects including nausea, vomiting,?
GI side effects including nausea, vomiting, and diarrhea occur in a significant portion of semaglutide users. Severe, prolonged vomiting can cause electrolyte imbalances, which carry their own serious risks.
What does the video say about obtaining semaglutide?
Obtaining semaglutide or any prescription GLP-1 medication through unofficial or unregulated channels means no verification of drug purity, concentration, or dose, and no clinical monitoring if adverse effects occur.
What does the video say about rapid weight loss at a rate exceeding 1 to 2?
Rapid weight loss at a rate exceeding 1 to 2 pounds per week is associated with muscle mass loss, reduced bone density, and cardiovascular strain, particularly in individuals already at low body weight.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by X03, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.